Document is current
Any future updates will be listed below
-
Authors
-
Funding
Funding for this research was provided by:
Novo Nordisk Ltd
- License Information
-
More Information
Article History
Received: 14 February 2025
Accepted: 1 April 2025
First Online: 28 May 2025
Declarations
:
: Ryo Suzuki: received lecture fees from Astellas Pharma Inc., Eli Lilly Japan K.K., Kowa Company Ltd., Mitsubishi Tanabe Pharma Corporation, MSD K.K., Novo Nordisk Pharma Ltd., Sanofi K.K., Sumitomo Pharma Co., Ltd., Teijin Healthcare Ltd.; and grants from Nippon Boehringer Ingelheim Co., Ltd., Krishant Chand and Yuu Taguchi are employed by Novo Nordisk Pharma Ltd. Yuu Taguchi is a shareholder in Novo Nordisk Pharma Ltd.
: The study was conducted in accordance with the Declaration of Helsinki and the Guidelines for Good Pharmacoepidemiology Practices. The study protocol, consent forms, and questionnaires were approved by an independent ethics committee of the Research Institute of Healthcare Data Science (approval number RI2023005) on December 4, 2023. All respondents provided informed consent online, and were made aware and gave consent that their responses would be published in a medical journal. All personal information was managed by Macromill, Inc. (Tokyo, Japan), was used solely for the purposes of this study, and was not provided to the study sponsor.
